📰 Keith Blundy News

Keith Blundy News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Keith Blundy. Real-time updates on events, politics, business and more.

PharmEnable Closes $7.5M Financing led by MP Healthcare to Develop Next Generation of Small Molecule Drugs to Treat Cancer and Neurological Diseases

May 23, 2023

PharmEnable, a drug discovery company focused on chemical novelty, diversity and complexity, announces it has closed a Pre-Series A investment round of $7.5M to develop the next generation of small molecule drugs against disease areas of high clinical need. The funding round was led by MP Healthcare Venture ...

United Kingdom Sosei Heptares Keith Blundy Jeffrey Moore Christine Martin Jonathan Milner

Source: pharmiweb.com

PharmEnable Closes $7.5M Pre-Series Financing

May 22, 2023

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

United Kingdom Jonathan Milner Christine Martin Sosei Heptares Keith Blundy Jeffrey Moore

Source: finsmes.com

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

October 14, 2021

STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform ALAMEDA, Calif. and CAMBRIDGE, England,

United Kingdom Tony Kouzarides Keith Blundy Eric Miska Peter Lamb Prnewswire Exelixis Inc

Source: finanznachrichten.de

Exelixis, Inc.: Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

October 14, 2021

STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform - Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics

United Kingdom Tony Kouzarides Eva Haas Varant Shirvanian Hal Mackins Keith Blundy